FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
The landscape of rare coagulation factor deficiency management in Italy: a national hemophilia center survey
1046PDF: 141HTML: 40Appendix: 69 -
Diagnostic and management practices for inherited fibrinogen disorders: a nationwide survey of Italian Hemophilia Treatment Centers
437PDF: 64HTML: 49Supplementary: 27Appendix: 42 -
PO27 | B-cell lymphoproliferative disorder and acquired coagulopathy: an insidious link C. Caputo, P. Conca, I.L. Calcaterra, E. Cimino, M. Romeo, M. Aversano, E. Franco, C. De Luca, R. Russo, C. Fierarossa, M.N.D. Di Minno, A. Tufano | Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy
476PDF: 0 -
The key to fibrinolysis and thrombolysis
1510PDF: 272HTML: 127 -
PO42 | Acquired Von Willebrad syndrome in patients with myeloproliferative syndrome: literature review and single-center experience A. Strangio, M. Leotta, A. Ierardi, R C. Santoro | UO Emofilia, Emostasi e Trombosi, AOU R Dulbecco, Catanzaro, Italy
434PDF: 0 -
PO77 | The clinical awareness of mixing test interpretation in the era of complex reporting algorithm: do we forget the origins? A. Fassina, L. De Valentin, S. Luzi, R. Turrini, A. Antico, L. Zardo | Laboratorio Analisi Castelfranco Veneto, ULSS Marca Trevigiana, Italy
507PDF: 0 -
PO01 | MELANOMA-DERIVED EXTRACELLULAR VESICLES DRIVE VON WILLEBRAND FACTOR–DEPENDENT THROMBOSIS AND METASTASIS Y. Wang1|2, X. Liu1, T. Downar3, A. Topuz4, A. Bauer1, J. Kött1|5, K. Nekipelov6, S. Brenna7, G. Bendas6, B. Puig7, S. Schneider1, D. Fedosov4, C. Gorzelanny1 | 1Department of Dermatology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 2Mildred Scheel Cancer Career Center HaTriCS4, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 3Experimental Dermatology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; 4Institute for Advanced Simulation (IAS-2), Forschungszentrum Jülich, Jülich, Germany; 5Fleur Hiege Center for Skin Cancer Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 6Pharmaceutical Institute, University of Bonn, Bonn, Germany; 7Neurology Department, Experimental Research in Stroke and Inflammation (ERSI), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
104PDF: 23 -
PO03 | HEPATIC FIBROSIS–DRIVEN TISSUE FACTOR EXPRESSION BY MALIGNANT CHOLANGIOCYTES IS ASSOCIATED WITH CANCER-ASSOCIATED THROMBOSIS AND POOR SURVIVAL IN INTRAHEPATIC CHOLANGIOCARCINOMA L. Fabris1|2|3, Y. Frión-Herrera1, C. Venturin1|3, M. Cadamuro4, J. Gasparello5, C. M. Radu1|2, M. Fassan1|5, C. Mescoli6, U. Cillo7|8, E. Gringeri7|8, G. Zanus7|9, E. Campello1|2, M. Strazzabosco3, P. Simioni1|2 | 1Department of Medicine, University of Padua; 2Clinical Medicine 1 and Thrombotic and Haemorrhagic Disease Unit, and Haemophilia Center, Padua University-Hospital; 3Department of Internal Medicine, Digestive Disease Section, Liver Center, Yale University, New Haven, CT, USA; 4School of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy; 5Pathology Unit, Ca' Foncello Hospital, ULSS2 Marca Trevigiana, Treviso; 6Pathology Unit, Padua University-Hospital; 7Department of Surgery, Oncology and Gastroenterology, University of Padua; 8Hepatobiliary Surgery and Liver Transplantation Unit, Padua University-Hospital; 9General Surgery Unit, Ca' Foncello Hospital, ULSS2 Marca Trevigiana, Treviso, Italy
98PDF: 19 -
OC13 | VON WILLEBRAND FACTOR PREDICTS POOR OUTCOME IN PANCREATIC CANCER AND MEDIATES TUMOR-ENDOTHELIUM INTERACTIONS FACILITATING METASTASIS B. Ünlü1, Z. Zhao1, N. Joshi1, S. De1, A. Chion1, I. Schoen1, J. O’Donnell1, M. Flick2, M. Fishel3|4, J. O’Sullivan1 | 1School of Pharmacy and Biomolecular Sciences, Irish Centre for Vascular Biology, Royal College of Surgeons in Ireland, Dublin, Ireland; 2UNC Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, USA; 3IU Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA; 4Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA
107PDF: 20 -
PO20 | DYSFUNCTION OF THE ADAMTS-13/VON WILLEBRAND FACTOR AXIS, MEDIATED BY NETOSIS, AS A DRIVER OF PROTHROMBOTIC STATE AND UNFAVORABLE PROGNOSIS IN ONCOGYNECOLOGICAL PATIENTS V. Bitsadze1, E. Beloborodova2, J. Khizroeva1, A. Solopova1, M. Tretyakova1, N. Gashimova1, K. Grigoreva1, A. Tatarintseva1, J. Christophe Gris1|3, I. Elalamy1|4|5, G. Gerotziafas1|4|5, A. Makatsariya1 | 1Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children’s Health, I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 2Clinic MEDSI Network of Medical Centers in Moscow, Russia; 3Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France; 4Department Hematology and Thrombosis Center, Medicine Sorbonne University, Paris, France; 5Hospital Tenon, Paris, France
109PDF: 23 -
PO39 | Bleeding events in Von Willebrand disease type 1 yearly treatable with desmopressin A. Gringeri1,2, P.M. Mannucci3, M. Gringeri4, G. Castaman5, F. Peyvandi3,6 | 1Fondazione Charta, Milan; 2Centro di Sanità Solidale, Lucca; 3Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan; 4Department of Medical Biotechnologies and Translational Medicine, Postgraduate School of Clinical Pharmacology and Toxicology, University of Milan; 5Centre for Bleeding Disorders and Coagulation, Careggi University Hospital, Firenze; 6Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Italy
502PDF: 0 -
CO02 | Hepatic fibrosis as predictor of cancer-associated thrombosis in patients with intrahepatic cholangiocarcinoma Y. Frion-Herrera1,2, C. Venturin1,3, M. Cadamuro4, J. Gasparello5, C.M. Radu1, M. Fassan5, C. Mescoli6, U. Cillo7, E. Gringeri7, G. Zanus8, L. Fabris1,3, P. Simioni1 | 1Clinical Medicine and Thrombotic and Haemorrhagic Disease Unit, and Haemophilia Center, Padua University-Hospital, Department of Medicine [DIMED], University of Padua, Italy; 2Department of Biology [DiBio], University of Padua, Italy; 3Department of Internal Medicine, Digestive Disease Section, Liver Center, Yale University, New Haven, CT, USA; 4School of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy; 5Department of Pathology Ca’ Foncello Hospital, ULSS2 Marca Trevigiana, Italy; 6Pathology Unit, Padua University-Hospital, Padua, Italy; 7Hepatobiliary Surgery and Liver Transplantation Unit, Padua University-Hospital, Department of Surgery, Oncology and Gastroenterology [DISCOG], University of Padua, Italy; 8General Surgery Unit, Ca’ Foncello Hospital, ULSS2 Marca Trevigiana, Department of Surgery, Oncology and Gastroenterology [DISCOG], University of Padua, Italy
572PDF: 0 -
PO23 | Plasmic score applicability for the diagnosis of thrombotic microangiopathy associated with acquired ADAMTS13 deficiency in emergency settings at the hub laboratory of AUSL Romagna: state of the art and future prospects M. Olivieri1, M. Rosetti1, A. Clementoni1, V. Marinucci1, M. Monterosso1, E. Massari1, V. Polli1, M. Zauli1, V. Sambri2 | 1Clinical Pathology Unit; 2Unit of Microbiology, Area Hub Laboratory, Cesena, Italy
509PDF: 0 -
CO21 | Viscoelastic testing in inherited bleeding disorders: a cross-sectional comparison between viscoelastic coagulation monitoring and rotational thromboelastometry C. Simion, C. Samà, C. Bulato, G. Gottardi, D. Regazzo, E. Campello, P. Simioni | Department of Medicine – DIMED, University of Padua, Italy
487PDF: 0 -
PO19 | THE INTER-RELATIONSHIP BETWEEN NETOSIS, THE ADAMTS-13/VWF AXIS, AND HEMOSTATIC ACTIVATION IN PATIENTS WITH GYNECOLOGICAL MALIGNANCIES: PROGNOSTIC SIGNIFICANCE AND IMPACT OF CHEMOTHERAPY A. Makatsariya1, E. Beloborodova2,V. Bitsadze1, J. Khizroeva1, A. Vorobev1, A. Solopova1, M. Tretyakova1, N. Gashimova1, K. Grigoreva1, A. Oskolkova1, J. Christophe Gris1|3, I. Elalamy1|4|5, G. Gerotziafas1|4|5 | 1Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children’s Health, I. M. Sechenov First Moscow State Medical University Sechenov University, Moscow, Russia; 2MEDSI Network of Medical Centers, Moscow, Russia; 3Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France; 4Department Hematology and Thrombosis Center, Medicine Sorbonne University, Paris, France; 5Hospital Tenon, Paris, France
95PDF: 27 -
PO17 | PREDICTIVE VALUE OF INFLAMMATORY AND ENDOTHELIAL BIOMARKERS FOR CANCER RISK IN HEALTHY INDIVIDUALS: EVIDENCE FROM THE HYPERCAN STUDY C. Ticozzi1, S. Bolognini1|2, P. Gomez-Rosas1|3, F. Schieppati1|2, G. Sampietro4, L. Barcella1, M. Marchetti1|2, A. Falanga1|2 | 1Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; 3Maastricht University Medical Center, Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands; 4Unit of Epidemiology and Statistics, ATS Bergamo, Italy
90PDF: 24 -
PO12 | Characterisation and real word clinical data of HEM006, a newly formulated intranasal spray desmopressin (DDAVP) to address a global treatment gap G. De Giorgi1, A. Gringeri2, R. Franceschini1, A. Koganti3 | 1Hemorare Srl, Italy; 2Fondazione Charta, Milan, Italy; 3Quenya LLC, USA
437PDF: 0 -
PO10 | Clinical and laboratory features of long-Covid syndrome: a cross-sectional study of 1,337 Covid-19 survivors C. Ambaglio1, S. V. Benatti2, C. J. Tartari1,3, L. Russo1,3, S. Bolognini1,3, C. Ticozzi1, F. Schieppati1, V. Brusegan1, S. Venturelli2, L. Barcella1, M. Rizzi2, M. Marchetti1,3, A. Falanga1,3 | 1Department of Immunohematology and Transfusion Medicine, Papa Giovanni XXIII Hospital, Bergamo; 2Division of Infectious Diseases, Papa Giovanni XXIII Hospital, Bergamo; 3Department of Medicine and Surgery, University of Milan Bicocca, Monza, Italy
502PDF: 0 -
CO23 | Markers of inflammation and hypofibrinolysis are associated with cognitive dysfunction and motor performances in atrial fibrillation patients on oral anticoagulant therapy: insights from the Strat-AF study F. Alfano1,2, F. Cesari1,2, A.M. Gori1,2, M. Berteotti1,2, E. Salvadori3, B. Giusti1,2, A. Bertelli1,2, F. Fratini4, A. Rogolino1,2, B. Formelli4,5, F. Pescini4,5, E. Fainardi6, E. Barucci4, G. Salti5, A. Cavaliere4, A. Ginestroni6, A. Poggesi4,5, R. Marcucci1,2 | 1Department of Experimental and Clinical Medicine, University of Firenze; 2Center for Atherothrombotic Diseases, Careggi University Hospital, Firenze; 3Department of Biomedical and Clinical Sciences, University of Milan; 4NEUROFARBA Department, Neuroscience Section, University of Firenze; 5Stroke Unit, Careggi University Hospital, Firenze; 6Neuroradiology Unit, Careggi University Hospital, Department of Experimental and Clinical Biomedical Sciences, University of Firenze, Italy
566PDF: 0
1 - 22 of 22 items
